Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21660948 | 0.91 | NPC1 (0.56) | HDAC6NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL21660946 | 0.84 | ALDH1A1 (0.58) | HDAC6NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL21643745 | 0.83 | NPC1 (0.66) | HDAC6NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL2117506 | 0.81 | CYP3A4 (0.53) | HDAC6NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL2611323 | 0.81 | HDAC6 (0.55) | HDAC6NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL20547965 | 0.81 | HDAC1 (0.54) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL14263316 | 0.76 | NPC1 (0.67) | NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL12412028 | 0.75 | NPC1 (0.63) | NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL4980463 | 0.74 | NPC1 (0.60) | NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL19058676 | 0.73 | HDAC6 (1.00) | HDAC6HDAC1HDAC8HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934255-B2 | Nrf and HIF activators/HDAC inhibitors and therapeutic methods using the same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2021-03-02 | — | — | US | disclosed |
| US-10934255-B2 | Nrf and HIF activators/HDAC inhibitors and therapeutic methods using the same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200039933-A1 | NRF AND HIF ACTIVATORS/HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2020-02-06 | — | — | US | disclosed |
| US-20200039933-A1 | NRF AND HIF ACTIVATORS/HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2020-02-06 | — | — | US | disclosed |
| CN-110730660-A | Nrf and HIF activators/HDAC inhibitors and methods of treatment using the same | 伊利诺伊大学评议会 | 2020-01-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934255-B2 | Nrf and HIF activators/HDAC inhibitors and therapeutic methods using the same | HIF1AN, KEAP1, NFE2L2 | HDAC6 35/4885NPC1 1029/4885RAB9A 2126/4885 |
| US-20200039933-A1 | NRF AND HIF ACTIVATORS/HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | HIF1AN, KEAP1, NFE2L2 | HDAC6 35/4885NPC1 1029/4885RAB9A 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.